View Exam | PowerPak

1. What is the cause of bleeding events, such as intracranial hemorrhage, in patients receiving oral anticoagulation?

A. the mechanism of the anticoagulant, such as vitamin K inhibition or factor Xa inhibition B. damage or rupture to large or small blood vessels C. both A and B (anticoagulant use plus damage to blood vessels) D. concomitant use of antiplatelet agents E. unsure

2. Bleeding risk is increased when the dosage of an oral anticoagulant is outside of the targeted therapeutic range. This is most likely to occur for patients taking:

A. edoxaban B. dabigatran C. any Factor Xa inhibitor D. warfarin E. unsure

3. Reversal of direct oral anticoagulants (DOACs) that act via Factor Xa inhibition is best achieved using what method or agent?

A. idarucizumab B. ciraparantag C. andexanet alfa D. prothrombin complex concentrate (PCC) E. unsure

4. Guidelines that cover criteria for a major versus minor bleeding event, current DOAC reversal strategies, and when to restart anticoagulation is:

A. 2020 American College of Cardiology (ACC) Consensus Decision Pathway B. 2018 CHEST Guideline on Antithrombotic Therapy for Atrial Fibrillation C. 2018 American Society of Hematology (ASH) Venous Thromboembolism Treatment Guidelines D. All of the above E. Unsure

5. Revised National Patient Safety Goals from The Joint Commission, relating to anticoagulation management in the hospital, stipulate that:

A. Institutions must follow the ACC consensus decision pathway for reversal of oral anticoagulation B. Institutions may develop a protocol, or may allow clinicians to act independently according to local best practices C. Institutions must develop a protocol for management of oral anticoagulant-associated bleeding D. Institutions must report all bleeding events to the Joint Commission E. Unsure

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What is the cause of bleeding events, such as intracranial hemorrhage, in patients receiving oral anticoagulation?

2. Bleeding risk is increased when the dosage of an oral anticoagulant is outside of the targeted therapeutic range. This is most likely to occur for patients taking:

3. Reversal of direct oral anticoagulants (DOACs) that act via Factor Xa inhibition is best achieved using what method or agent?

4. Guidelines that cover criteria for a major versus minor bleeding event, current DOAC reversal strategies, and when to restart anticoagulation is:

5. Revised National Patient Safety Goals from The Joint Commission, relating to anticoagulation management in the hospital, stipulate that:

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What is the cause of bleeding events, such as intracranial hemorrhage, in patients receiving oral anticoagulation?

2. Bleeding risk is increased when the dosage of an oral anticoagulant is outside of the targeted therapeutic range. This is most likely to occur for patients taking:

3. Reversal of direct oral anticoagulants (DOACs) that act via Factor Xa inhibition is best achieved using what method or agent?

4. Guidelines that cover criteria for a major versus minor bleeding event, current DOAC reversal strategies, and when to restart anticoagulation is:

5. Revised National Patient Safety Goals from The Joint Commission, relating to anticoagulation management in the hospital, stipulate that:

« Return to Activity

Customers who Purchased
this Activity also Purchased